- Home
- PIII vs ITRM Comparison
PIII vs ITRM Comparison
Compare PIII & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ITRM
- Stock Information
- Founded
- PIII 2015
- ITRM 2015
- Country
- PIII United States
- ITRM Ireland
- Employees
- PIII N/A
- ITRM N/A
- Industry
- PIII Medical/Nursing Services
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ITRM Health Care
- Exchange
- PIII Nasdaq
- ITRM Nasdaq
- Market Cap
- PIII 30.8M
- ITRM 36.3M
- IPO Year
- PIII N/A
- ITRM 2018
- Fundamental
- Price
- PIII $6.62
- ITRM $0.97
- Analyst Decision
- PIII Buy
- ITRM Strong Buy
- Analyst Count
- PIII 2
- ITRM 2
- Target Price
- PIII $16.25
- ITRM $7.00
- AVG Volume (30 Days)
- PIII 5.1K
- ITRM 515.1K
- Earning Date
- PIII 05-15-2025
- ITRM 05-13-2025
- Dividend Yield
- PIII N/A
- ITRM N/A
- EPS Growth
- PIII N/A
- ITRM N/A
- EPS
- PIII N/A
- ITRM N/A
- Revenue
- PIII $1,485,192,000.00
- ITRM N/A
- Revenue This Year
- PIII N/A
- ITRM N/A
- Revenue Next Year
- PIII $6.01
- ITRM $108.39
- P/E Ratio
- PIII N/A
- ITRM N/A
- Revenue Growth
- PIII 9.79
- ITRM N/A
- 52 Week Low
- PIII $6.47
- ITRM $0.81
- 52 Week High
- PIII $33.73
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- PIII 30.04
- ITRM 45.57
- Support Level
- PIII $6.47
- ITRM $0.93
- Resistance Level
- PIII $7.45
- ITRM $1.05
- Average True Range (ATR)
- PIII 0.29
- ITRM 0.05
- MACD
- PIII -0.09
- ITRM 0.01
- Stochastic Oscillator
- PIII 8.26
- ITRM 50.00
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.